EN DE
Watch NaviFUS Corp. for free: we tell you when fair value or trend changes.
Data-driven stock valuation

NaviFUS Corp. (6872) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of NaviFUS Corp. stock TWD 11.18, price TWD 17.75, that is 37.0% below the price, quality 27 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare TW

NC NaviFUS Corp. logo Thin data Nov 10, 2026

NaviFUS Corp.

6872 · TWO
Very expensive, weak quality

Our calculation puts a fair price 37% below what the stock costs today.

Fair value 11.18 TWD · Strongly overvalued
Quality 27/100
Weak Growth (revenue 3y −18.7 %/yr in TWD)
Negative free cash flow
Trails peers (2/7)
Narrow moat 18/100
Thin data
Estimate
Watch NaviFUS Corp. for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

39.65 TWD 14.00 TWD Fair Value 11.18 TWD Jun 2022 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

53‑month range 14.00 TWD – 39.65 TWD · fair‑value band 8.38 TWD – 13.97 TWD · the 17.75 TWD price screens above the 11.18 TWD fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.

Follow NaviFUS in your weekly email

Every Wednesday you see whether NaviFUS is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

NaviFUS Corp., a medical device company, develops and sells focused ultrasound (FUS) solutions for the unmet needs in neuromedicine in Taiwan.

Show moreShow less

The company develops NaviFUS, a neuronavigator-guided transcranial FUS system that delivers focal energy into deep tissues in the brain, as well as is used in various clinical applications, such as drug delivery, neuromodulation, immuno-stimulation, and others.

It also develops NAVIRFA, a navigation system that uses optical 3D surgical tracking technology to monitor the 3D position of the needle tip during ultrasonic interventional procedures. The company was founded in 2015 and is based in Taipei, Taiwan.

Stock analysis

NaviFUS Corp. (6872) currently trades at 17.75 TWD, while our estimate is 11.18 TWD, 37% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: 8.38 TWD (bear) to 13.97 TWD (bull), the price of 17.75 TWD sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 27/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

NaviFUS Corp. reported revenue of 10.5M TWD in FY2025 versus 0 TWD in FY2021. Reported net income was −148M TWD in FY2025.

Key figures

Market cap 1.3B TWD (≈ $38.2M) Micro · EPS (TTM) −2.12 TWD · Return on assets (EBIT) −17.8% (5-year average) · Free cash flow −139M TWD.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 18 out of 100 (medium confidence).

What moves the price

The share trades about 34% below its 52-week high and 27% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at 8% fair-value upside, at −37%, 6872 screens richer than that median.

Fair Value

Bear 8.38 TWD Fair Value 11.18 TWD Bull 13.97 TWD
Price 17.75 TWD · Downside -37.0%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 27/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 7
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 100
Debt, balance sheet and risk of trouble
Investment 48
Does it invest with discipline instead of growing at any price?
Low Volatility 34
How calm the share price moves, does not count
Price momentum 49
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 24
Distance to the 52-week high, does not count
New shares 2
Buys back shares or issues new ones?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−61.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.7%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−373.3% (2022) → −1,523.4% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

6872 screens overvalued: fair value 37% below the price. Compare with Abbott Laboratories, →

Compare NaviFUS Corp. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 402 stocks

Beats the industry median on 1/6 measures
Overall it trails its industry peers.
Valuation
Quality Score 27 · Bottom 25%
Fair Value upside −37.0% · Bottom 25%
Profitability
Return on assets −23.3% · Bottom 25%
Operating margin (12 months) 0.0% · Below median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Below median

Valuation Multiplesvs Medical Devices median · lower = cheaper

P/B 0.07× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Devices stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Shenzhen Mindray Bio-Medical Electronics Co 300760 ¥178.92 ¥202.57 +13% vs 6872
DexCom, Inc DXCM $79.92 $89.18 +12% vs 6872
Stryker Corporation SYK $324.29 $358.30 +10% vs 6872
STERIS plc STE $257.12 $279.53 +9% vs 6872
Boston Scientific Corporation BSX $44.70 $48.42 +8% vs 6872
GE HealthCare Technologies Inc GEHC $83.65 $69.92 −16% vs 6872
Edwards Lifesciences Corporation EW $104.01 $81.94 −21% vs 6872
Abbott Laboratories, ABT $110.46 $75.28 −32% vs 6872
Medtronic plc MDT $101.59 $65.61 −35% vs 6872
Koninklijke Philips N.V PHIA €27.06 €15.23 −44% vs 6872

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

NaviFUS Corp.: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "NaviFUS Corp. Fair Value". https://www.fairvalue-calculator.com/stock/6872.TWO

Frequently asked questions

Is NaviFUS Corp. (6872) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is 11.18 TWD versus a price of 17.75 TWD, about 37% lower (overvalued).
What is the fair value of 6872?
Our estimate for NaviFUS Corp. is 11.18 TWD (as of Nov 10, 2026), built from audited fundamentals. The current price: 17.75 TWD.
What is the quality score of 6872?
NaviFUS Corp. has a Quality Score of 27/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for NaviFUS Corp. (6872)?
Our calculated price target is the estimate of 11.18 TWD (as of Nov 10, 2026). Cautious scenario 8.38 TWD, optimistic scenario 13.97 TWD. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the NaviFUS Corp. stock forecast for 2026?
Our estimate puts fair value at 11.18 TWD, about 37% lower versus a price of 17.75 TWD (overvalued). Cautious scenario 8.38 TWD, optimistic scenario 13.97 TWD. The calculation is refreshed regularly with new filings.
What is the intrinsic value of NaviFUS Corp. (6872)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For NaviFUS Corp. it is 11.18 TWD per share (as of Nov 10, 2026), against a price of 17.75 TWD.
Is NaviFUS Corp. stock overvalued or undervalued in 2026?
As of Nov 10, 2026, 6872 trades above its calculated fair value: price 17.75 TWD, fair value 11.18 TWD, a gap of about −37% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 6872?
No. The price is what the market pays today (17.75 TWD); the fair value is what the company's own numbers justify (11.18 TWD). For NaviFUS Corp. the two are 6.57 TWD per share apart. That gap is exactly why we show both numbers side by side.
How much is NaviFUS Corp. worth?
The market values NaviFUS Corp. at about 1.3B TWD (market capitalisation, as of Nov 10, 2026). Per share that is 17.75 TWD; our models calculate a fair value of 11.18 TWD per share.
What do the bullish and bearish scenarios say about 6872?
Our models span a range for NaviFUS Corp.: cautious scenario 8.38 TWD, base 11.18 TWD, optimistic 13.97 TWD per share (as of Nov 10, 2026, price 17.75 TWD). The range comes from different growth and margin assumptions, not from analyst opinions.
How far is 6872 from its 52-week high?
NaviFUS Corp. trades at 17.75 TWD, about 34% below its 52-week high of 26.75 TWD and 27% above the low of 14.00 TWD (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of 11.18 TWD is for.
Which stocks are comparable to NaviFUS Corp.?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is NaviFUS Corp. stock attractive at the current price?
The data as of Nov 10, 2026: price 17.75 TWD, calculated fair value 11.18 TWD (−37%), Quality Score 27/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. NaviFUS Corp. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of NaviFUS Corp. (6872)?
The closing price on Nov 10, 2026 was 17.75 TWD. Our estimate is 11.18 TWD, about 37% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with NaviFUS Corp. right now?
The price sits above even our optimistic bull case (13.97 TWD). The favourable scenario is already priced in. Weak quality (27/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of NaviFUS Corp.

How large is the market capitalisation of NaviFUS Corp. (6872)?
The market capitalisation of NaviFUS Corp. is 1.3B TWD (≈ $38.2M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of NaviFUS Corp. (6872)?
Earnings per share at NaviFUS Corp. are −2.12 TWD. Earnings per share over the last twelve months: total profit spread across every single share.
What is the EBIT return on assets of NaviFUS Corp. (6872)?
On an EBIT basis the return on assets of NaviFUS Corp. is −17.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does NaviFUS Corp. (6872) generate?
The free cash flow of NaviFUS Corp. is −139M TWD (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch NaviFUS Corp. in the live analysis

One click puts NaviFUS Corp. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.